AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27942734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (N=354) with reduced worktime to 75% for 18 months
Number of subjects: 580
Study 27942734 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 580
Study 26058988 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for silent myocardial ischemia followed by revascularization
Number of subjects: 520
Study 26058988 — intervention group
Group type: COMPARATOR
Intervention: Follow-up without screening
Number of subjects: 520
Study 26058988 — intervention group
Group type: EXPERIMENTAL
Intervention: Older than 60 years
Number of subjects: 520
Study 22820124 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking condition
Number of subjects: 179
Study 22820124 — intervention group
Group type: COMPARATOR
Intervention: Flexibility, toning, and balance condition
Number of subjects: 179
Study 22186072 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine-sulphonamide treatment for 3 months followed by Fansidar(®) for 9 months
Number of subjects: 486
Study 22186072 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic abstention
Number of subjects: 486
Study 19154810 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Folin-Ciocalteu method using Oasis MAX 96-well plate cartridges for solid phase extraction
Number of subjects: 60
Study 19154810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sectional study
Number of subjects: 60
Study 16319099 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-strengthening and mobilizing home exercises (Group 1)
Number of subjects: 67
Study 16319099 — intervention group
Group type: COMPARATOR
Intervention: Hand-stretching exercises (Group 2)
Number of subjects: 67
Study 16319099 — intervention group
Group type: COMPARATOR
Intervention: Joint protection information alone (Group 3)
Number of subjects: 67
Study 15479589 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable gastric stimulation (IGS) activated group
Number of subjects: 133
Study 15479589 — intervention group
Group type: COMPARATOR
Intervention: Implantable gastric stimulation (IGS) non-activated group
Number of subjects: 133
Study 15479589 — intervention group
Group type: EXPERIMENTAL
Intervention: DIGEST trial with IGS
Number of subjects: 133
Study 15479589 — intervention group
Group type: EXPERIMENTAL
Intervention: Selected patients with preoperative screening algorithm
Number of subjects: 133
Study 11049014 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed drugs
Number of subjects: 492
Study 11049014 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-counter (OTC) drugs
Number of subjects: 492
Study 11049014 — intervention group
Group type: EXPERIMENTAL
Intervention: Central nervous system (CNS) drugs
Number of subjects: 492
Study 11049014 — intervention group
Group type: EXPERIMENTAL
Intervention: OTC drugs
Number of subjects: 492
Study 11049014 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential drug interactions
Number of subjects: 492
Study 9052345 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 or 20 mg) and Felodipine ER (2.5, 5, or 10 mg)
Number of subjects: 707
Study 9052345 — intervention group
Group type: COMPARATOR
Intervention: Felodipine ER monotherapy
Number of subjects: 707
Study 9052345 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril-Felodipine ER combinations
Number of subjects: 707
Study 9052345 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg) and Felodipine ER (10 mg)
Number of subjects: 707
Study 9052345 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg) and Felodipine ER (2.5 mg)
Number of subjects: 707
Study 8305650 — intervention group
Group type: EXPERIMENTAL
Intervention: Two levels of blood pressure control and two dietary interventions
Number of subjects: 840
Study 8305650 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary control of protein and phosphorus
Number of subjects: 840
Study 8305650 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure control
Number of subjects: 840
Study 8305650 — intervention group
Group type: EXPERIMENTAL
Intervention: Study A and Study B
Number of subjects: 840
Study 3329515 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg benzhexol
Number of subjects: 2
Study 3329515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 29472432 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate treatment
Number of subjects: 17142
Study 27070250 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) treatment for 2 weeks, 14-minute sessions
Number of subjects: 11
Study 27070250 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 11
Study 27070250 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) treatment
Number of subjects: 11
Study 25023033 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential rescue therapies
Number of subjects: 0
Study 22230827 — intervention group
Group type: COMPARATOR
Intervention: escitalopram plus placebo
Number of subjects: 665
Study 22230827 — intervention group
Group type: COMPARATOR
Intervention: bupropion-SR plus escitalopram
Number of subjects: 665
Study 22230827 — intervention group
Group type: COMPARATOR
Intervention: venlafaxine-XR plus mirtazapine
Number of subjects: 665
Study 20001574 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 2652
Study 20001574 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 2652
Study 18710676 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported smoking in the previous 30 days
Number of subjects: 2209
Study 18710676 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported daily smoking
Number of subjects: 2209
Study 18710676 — intervention group
Group type: COMPARATOR
Intervention: Cotinine concentration cutoff of 10 ng/mL
Number of subjects: 2209
Study 18710676 — intervention group
Group type: COMPARATOR
Intervention: Cotinine concentration cutoff of 30 ng/mL
Number of subjects: 2209
Study 17221005 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with preoperative planning using neuroimaging, anatomical study, microsurgery technique, and cortical stimulation
Number of subjects: 42
Study 17221005 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical stimulation
Number of subjects: 42
Study 17221005 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotaxy method
Number of subjects: 42
Study 12891299 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin (10‐20 mg/day), clopidogrel (75 mg/day), and trimetazidine (60 mg/day) for 6 months
Number of subjects: 42
Study 12891299 — intervention group
Group type: COMPARATOR
Intervention: simvastatin and clopidogrel for 6 months
Number of subjects: 42
Study 11146601 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti epileptic medication
Number of subjects: 76
Study 11146601 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 76
Study 11146601 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal EEG
Number of subjects: 76
Study 11146601 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal EEG
Number of subjects: 76
Study 11146601 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of seizure
Number of subjects: 76
Study 11146601 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of seizure at initial presentation
Number of subjects: 76
Study 11146601 — intervention group
Group type: EXPERIMENTAL
Intervention: Time since first seizure
Number of subjects: 76
Study 8858649 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer treatment group
Number of subjects: 60
Study 8858649 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI-spacer treatment group 1
Number of subjects: 60
Study 8858649 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI-spacer treatment group 2
Number of subjects: 60
Study 8858649 — intervention group
Group type: COMPARATOR
Intervention: Comparison of all groups
Number of subjects: 60
Study 7961241 — intervention group
Group type: EXPERIMENTAL
Intervention: OSL training with audiovisual feedback; 15 treadmill sessions (30 min/day, 5 days/wk, 3 wk) at velocities of 2.87-3.74 m/s.
Number of subjects: 12
Study 7961241 — intervention group
Group type: COMPARATOR
Intervention: Control group performing treadmill running without feedback for 3 weeks.
Number of subjects: 12
Study 3300424 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ketamine (4, 6, and 8 mg in saline; 6 mg in 10% glucose)
Number of subjects: 68
Study 3300424 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (3 mg)
Number of subjects: 68
Study 3300424 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 68
Study 28962912 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar transforaminal epidural steroid injections (TFESIs)
Number of subjects: 78
Study 28962912 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 78
Study 27866386 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing with soap and water plus hand sanitizer (Experimental Group)
Number of subjects: 1341
Study 27866386 — intervention group
Group type: COMPARATOR
Intervention: Usual handwashing procedures (Control Group)
Number of subjects: 1341
Study 25596171 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitrous oxide
Number of subjects: 106
Study 25596171 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical infiltration with 1% lidocaine
Number of subjects: 106
Study 25596171 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 106
Study 23997095 — intervention group
Group type: EXPERIMENTAL
Intervention: PEMI after sublingual administration of 5 mg of isosorbide dinitrate (ISDN)
Number of subjects: 10
Study 23997095 — intervention group
Group type: COMPARATOR
Intervention: Control exercise recovery (CER) session
Number of subjects: 10
Study 23997095 — intervention group
Group type: EXPERIMENTAL
Intervention: PEMI session
Number of subjects: 10
Study 23997095 — intervention group
Group type: EXPERIMENTAL
Intervention: CER after ISDN
Number of subjects: 10
Study 21261949 — intervention group
Group type: EXPERIMENTAL
Intervention: Liverpool Care Pathway for the dying patient (LCP-I) Program
Number of subjects: 0
Study 21261949 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 0
Study 18507819 — intervention group
Group type: EXPERIMENTAL
Intervention: Stamped addressed envelopes
Number of subjects: 477
Study 18507819 — intervention group
Group type: COMPARATOR
Intervention: Pre-paid business reply envelopes
Number of subjects: 477
Study 18507819 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost per returned item for stamped envelopes
Number of subjects: 477
Study 18507819 — intervention group
Group type: COMPARATOR
Intervention: Cost per returned item for pre-paid envelopes
Number of subjects: 477
Study 18507819 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost comparison excluding set up cost for pre-paid service
Number of subjects: 477
Study 16583466 — intervention group
Group type: EXPERIMENTAL
Intervention: Single SC doses of 0.5, 1.5, or 3.0 mg/kg
Number of subjects: 43
Study 16583466 — intervention group
Group type: EXPERIMENTAL
Intervention: SC doses of 100 mg every 2 weeks (3 injections)
Number of subjects: 43
Study 16583466 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg IV infliximab every 2 weeks (2 infusions) followed by 100 mg SC every 2 weeks (3 injections)
Number of subjects: 43
Study 16583466 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg IM every 2 weeks (3 injections)
Number of subjects: 43
Study 16583466 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg SC every 4 weeks (3 injections)
Number of subjects: 43
Study 14726973 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency fistulotomy
Number of subjects: 50
Study 14726973 — intervention group
Group type: COMPARATOR
Intervention: Conventional fistulotomy
Number of subjects: 50
Study 11075846 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 75 mg/day
Number of subjects: 33
Study 11075846 — intervention group
Group type: COMPARATOR
Intervention: Citalopram 20 mg/day
Number of subjects: 33
Study 11075846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 7830026 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive, multiple-risk factor modification programme
Number of subjects: 508
Study 7830026 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 508
Study 1978660 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine salicylate
Number of subjects: 0
Study 1978660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 354733 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 60
Study 354733 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 60
Study 354733 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 60
Study 354733 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine and Amitriptyline (both)
Number of subjects: 60
Study 30068245 — intervention group
Group type: EXPERIMENTAL
Intervention: GOAL intervention
Number of subjects: 81
Study 30068245 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study 30945515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent automatic bolus (N=40)
Number of subjects: 80
Study 30945515 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion (N=40)
Number of subjects: 80
Study 30945515 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 28760205 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation therapy with edoxaban
Number of subjects: 3400
Study 28760205 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation (control group)
Number of subjects: 3400
Study 28760205 — intervention group
Group type: COMPARATOR
Intervention: Aspirin or no antithrombotic therapy (control group)
Number of subjects: 3400
Study 25650159 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mometasone furoate (MF)
Number of subjects: 62
Study 25650159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 23186831 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 36
Study 23186831 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 36
Study 23186831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 21592754 — intervention group
Group type: EXPERIMENTAL
Intervention: RS + WBRT
Number of subjects: 21
Study 21592754 — intervention group
Group type: COMPARATOR
Intervention: S + WBRT
Number of subjects: 21
Study 21592754 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 21
Study 19351223 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac-paracetamol combination (100 mg aceclofenac + 500 mg paracetamol bid)
Number of subjects: 199
Study 19351223 — intervention group
Group type: COMPARATOR
Intervention: Aceclofenac alone (100 mg bid)
Number of subjects: 199
Study 19351223 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac-paracetamol combination
Number of subjects: 199
Study 19351223 — intervention group
Group type: COMPARATOR
Intervention: Aceclofenac alone
Number of subjects: 199
Study 17032347 — intervention group
Group type: EXPERIMENTAL
Intervention: Product of insulin sensitivity and insulin secretion (B-beta)
Number of subjects: 375
Study 17032347 — intervention group
Group type: EXPERIMENTAL
Intervention: Product B-beta
Number of subjects: 375
Study 17032347 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-off point for product B-beta
Number of subjects: 375
Study 14676562 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/fentanyl anesthesia
Number of subjects: 20
Study 14676562 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane/nitrous oxide/fentanyl anesthesia
Number of subjects: 20
Study 11444253 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel 100 mg/m2
Number of subjects: 577
Study 11444253 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel 75 mg/m2
Number of subjects: 577
Study 11444253 — intervention group
Group type: COMPARATOR
Intervention: BSC
Number of subjects: 577
Study 11444253 — intervention group
Group type: COMPARATOR
Intervention: vinorelbine 30 mg/m2 or ifosfamide 2 g/m2
Number of subjects: 577
Study 9136776 — intervention group
Group type: EXPERIMENTAL
Intervention: Pylorus-preserving Whipple (PPW)
Number of subjects: 20
Study 9136776 — intervention group
Group type: COMPARATOR
Intervention: Duodenum-preserving pancreatic head resection (DPPHR)
Number of subjects: 20
Study 8053664 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human nerve growth factor (rhNGF) intravenous or subcutaneous doses ranging from 0.03 to 1 micrograms/kg
Number of subjects: 0
Study 8053664 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human nerve growth factor (rhNGF) at doses above 0.1 microgram/kg
Number of subjects: 0
Study 8053664 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human nerve growth factor (rhNGF) subcutaneous doses
Number of subjects: 0
Study 8053664 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human nerve growth factor (rhNGF) intravenous doses
Number of subjects: 0
Study 8053664 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 2970218 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose medroxyprogesterone acetate plus mitomycin-C (MMC)
Number of subjects: 40
Study 2970218 — intervention group
Group type: COMPARATOR
Intervention: High-dose medroxyprogesterone acetate plus vindesine
Number of subjects: 40
Study 31674161 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback augmentation group (n = 12)
Number of subjects: 24
Study 31674161 — intervention group
Group type: COMPARATOR
Intervention: Medication-only (treatment as usual [TAU] group, n = 12)
Number of subjects: 24
Study 28857958 — intervention group
Group type: EXPERIMENTAL
Intervention: CCLS present during procedure (Group I)
Number of subjects: 86
Study 28857958 — intervention group
Group type: COMPARATOR
Intervention: No CCLS present during procedure (Group II)
Number of subjects: 86
Study 26099838 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 Dp
Number of subjects: 120
Study 26099838 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D
Number of subjects: 120
Study 26099838 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 120
Study 23024159 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse management arm
Number of subjects: 288
Study 23024159 — intervention group
Group type: COMPARATOR
Intervention: Feedback approach
Number of subjects: 288
Study 21218023 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief individual intervention focusing on insight enhancement (5 sessions)
Number of subjects: 41
Study 21218023 — intervention group
Group type: COMPARATOR
Intervention: Control group (identical treatment program without insight enhancement)
Number of subjects: 41
Study 19110596 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocytic CSF (neupogen) added to chemotherapy
Number of subjects: 0
Study 19110596 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (adriablastine+taxotere) without neupogen
Number of subjects: 0
Study 16860622 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation and plication (RAMP)
Number of subjects: 0
Study 16860622 — intervention group
Group type: COMPARATOR
Intervention: Conventional ligature and excision procedure (LEP)
Number of subjects: 0
Study 12905096 — intervention group
Group type: COMPARATOR
Intervention: Continuous exercise (CON) - walking at 60 to 75% of maximum aerobic capacity, 3 days per week, 30 minutes per session
Number of subjects: 0
Study 12905096 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exercise (INT) - two 15-minute sessions, 5 days per week
Number of subjects: 0
Study 12905096 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CON and INT)
Number of subjects: 0
Study 10739360 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (2 mg/m2) plus dexamethasone (8 mg/m2)
Number of subjects: 90
Study 10739360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (5.3 mg/m2) plus dexamethasone (8 mg/m2)
Number of subjects: 90
Study 10739360 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron (3.3 mg/m2) plus dexamethasone (8 mg/m2)
Number of subjects: 90
Study 10739360 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with IFO
Number of subjects: 90
Study 10739360 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with CDP/ADM
Number of subjects: 90
Study 8959118 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1 mg day‐1
Number of subjects: 213
Study 8959118 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) 2 mg day‐1
Number of subjects: 213
Study 1530423 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg isosorbide dinitrate once daily
Number of subjects: 126
Study 1530423 — intervention group
Group type: COMPARATOR
Intervention: 20 mg isosorbide dinitrate three times daily
Number of subjects: 126
Study 6199177 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of mexiletine (200 mg three times daily) and propranolol (20 mg three times daily)
Number of subjects: 14
Study 6199177 — intervention group
Group type: COMPARATOR
Intervention: Mexiletine alone
Number of subjects: 14
Study 6199177 — intervention group
Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 14
Study 29172972 — intervention group
Group type: EXPERIMENTAL
Intervention: Website reporting both qualitative (patient comments) and quantitative information
Number of subjects: 688
Study 29172972 — intervention group
Group type: EXPERIMENTAL
Intervention: Website augmented by a decision aid (labeling of patient comments)
Number of subjects: 688
Study 29172972 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-aided website further augmented by the presence of a trained navigator
Number of subjects: 688
Study 29172972 — intervention group
Group type: COMPARATOR
Intervention: Conventional website reporting only quantitative performance information
Number of subjects: 688
Study 30193337 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation (exercise and nutrition optimization)
Number of subjects: 68
Study 30193337 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68